Autosomal Dominant Optic Atrophy (ADOA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
_page-0001.jpg)
Autosomal dominant optic atrophy (ADOA) is a rare hereditary disorder characterized by progressive and irreversible vision loss in both eyes, typically commencing in the first decade of life. Approximately 80% of affected individuals manifest symptoms before age 10, with onset frequently occurring between ages 4 and 6. Hallmark clinical features of ADOA include central visual field defects and impaired color vision. The disease exhibits significant phenotypic variability among family members, making predicting visual acuity decline and progression challenging. Many affected children eventually progress to blindness. About 50% of individuals with ADOA do not meet driving standards, and up to 46% are classified as legally blind. A subset of approximately 20% of patients presents with a more severe phenotype known as ADOA “plus” syndrome, which encompasses additional non-ocular manifestations such as permanent hearing loss and other severe conditions impacting the nervous system and skeletal muscles. Mutations in the OPA1 gene account for approximately 65-90% of ADOA cases, with over 400 distinct OPA1 mutations documented. Most of these mutations lead to a significant reduction—up to 50%—in the normal levels of the OPA1 protein, resulting in haploinsufficiency due to only one functional copy of the gene. The inheritance pattern of ADOA is autosomal dominant, meaning each offspring of an affected individual has a 50% likelihood of inheriting the mutation, with males and females being equally affected. De novo mutations can also occur. Diagnosis is frequently made during school entry or incidentally while examining other affected family members. Ophthalmologists diagnose ADOA based on family history and clinical findings, such as optic disc pallor. Genetic testing is used to confirm the diagnosis. Differential diagnoses include nutritional deficiency, toxic optic neuropathy, and macular dystrophy. Despite the availability of genetic testing, it has yet to be widespread for this condition. Currently, no therapeutic interventions exist to prevent or halt the progression of vision loss nor to restore vision in individuals with ADOA.
Thelansis’s “Autosomal Dominant Optic Atrophy (ADOA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Dominant Optic Atrophy (ADOA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Autosomal Dominant Optic Atrophy (ADOA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Autosomal Dominant Optic Atrophy (ADOA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment